Company* (Country; Symbol) |
University/ Non-Profit@ |
Type Of Agreement |
Product Area |
Details (Date) |
| | ||||
Aclara |
Tokyo Metropolitan Institute of Medical Science (Japan) |
Service and supply agreement |
Aclara is providing acces to its eTag Assay System |
The institute, also called “Rinshoken,“ will use the product in the area of hypoxia-inducible factors in cells and tissues (10/1) |
Acorda |
Rush University Medical Center |
Licensing agreement |
Fampridine |
Acorda obtained an exclusive worlwide license to fampridine for multiple sclerosis (10/3) |
ActivBiotics |
University of Washington |
Licensing agreement |
For a suite of patents covering the diagnosis and treatment of arterial chlamydial granuloma |
ActivBiotics gains rights to the patents from the university (7/28) |
Advanced Bio/Chem |
Baylor College of Medicine |
Agreement |
To search for neuro-degenerative disease biomarkers |
Further terms were not disclosed (7/17) |
Agilent |
Donald Reynolds Cardiovascular Clinical Research Center at Stanford University |
Agreement |
To apply Agilent's gene expression and computational technology to analyze cardiovascular tissue samples |
Further terms were not disclosed (10/2) |
Alnylam |
Mayo Clinic and National Institutes of Health |
Research collaboration |
To apply Alnylam's RNAi technology to discovery of a causal pathway in Parkinson's disease |
Alnylam will identify and provide compounds that suppress alpha-synuclein expression; Mayo researchers will test compounds in various models; terms were not disclosed (10/30) |
Alnylam |
Stanford University |
Licensing agreement |
For intellectual property related to the method for inducing gene silencing through RNA interference in adult mammals |
The license encompasses the demonstration that delivery of synthetic small interfering RNA molecules to an adult mammal can induce in vivo silencing of a specific target gene (9/22) |
Alnylam |
Cancer Research Technology |
Licensing agreement |
For RNA interference- based therapeutics |
Alnylam gained an exclusive therapeutic license for its RNAi patent application titled “Inhibiting gene expression with dsRNA“ (7/29) |
Alnylam |
Massachusetts Institute of Technology |
Licensing agreement |
For RNA interference- based therapeutics |
Alnylam exclusively licensed a portfolio of patent applications in the field of RNAi therapeutics that covers a variety of drug delivery techniques for nucleic acid compounds (7/29) |
AlphaVax Inc.* |
National Institute of Allergy and Infectious Diseases |
Contract |
A five-year award to support development of a vaccine for HIV |
The $16.8M contract comes from the NIAID's Division of AIDS and will support work on the company's ArV system (10/20) |
Altea |
Centers for Disease Control and Prevention |
Cooperative Research and Development Agreement |
To evaluate Altea's PassPort delivery system for the delivery of influenza antigens to immune cells near the skin's surface |
Scientists will evaluate the use of the system to deliver influenza protein and gene-based antigens to induce, augment and/or broaden the overall protective immune response to influenza viruses of similar or different subtypes (8/25) |
Ambion Inc.* |
City of Hope National Medical Center and the Beckman Research Institute |
Licensing agreement |
For technology detailed in a patent application covering technologies for expressing small interfering RNA from PCR products |
Ambion gained an exclusive, worldwide research market license for the technology (7/23) |
Aphios Corp.* |
National Institutes of Health and the U.S. Army Medical Research Institute |
Cooperative agreement |
To test Aphios' library of molecules from unique marine microorganisms for the prevention or treatment of severe acute respiratory syndrome and other coronavirus infections |
Aphios plans to discover and develop anti-SARS and anticoronavirus drugs (9/3) |
Avecia |
National Institute of Allergy and Infectious Diseases |
Contract |
To produce 3 million doses of a new recombinant anthrax vaccine |
The work continues efforts started in a 2002 award to produce 2,000 doses, and will be done with help from Baxter HealthCare Corp. (9/30) |
Bavarian Nordic A/S (Denmark; CSE:BAVA) |
National Institute of Allergy and Infectious Diseases |
Contract award |
To further develop MVA-BN as a smallpox vaccine |
Bavarian Nordic can receive up to $23M for developing the vaccine candidate, which is nearing Phase I studies in the U.S.; the award was part B of a two-part program (9/25) |
Benitec Ltd. (Australia; ASX:BLT) |
Garvan Institute of Medical Research (New South Wales) |
Collaboration |
To investigate the role of specific genes in Type II diabetes |
Benitec will provide Garvan with an increased number of its DNA-directed RNA interference constructs directed against an expanded range of potential drug targets; Benitec retains a first option to commercial rights to any resulting intellectual property and therapies against the gene targets (7/17) |
Bioenvision Inc. (AMEX:BIV) |
Southern Research Institute |
Exclusive option agreement |
To manufacture, market and distribute clofarabine, a drug to treat leukemias, in Japan and Southeast Asia |
Bioenvision said it is seeking a co-marketing partner to convert the option into a license on terms to be agreed upon between itself and the institute (9/10) |
Bioenvision Inc. (AMEX:BIV) |
Oklahoma Medical Research Foundation |
Research agreement |
To continue the development of methylene blue for the treatment of West Nile virus |
The compound is in use in parts of Europe, where it is used to inactivate viruses in vitro (8/12) |
Cangene Corp. |
National Institute of Allergy and Infectious Diseases |
Research project |
For a project to develop monoclonal antibodies to Burkholderia bacteria |
Cangene is partnering with Defence R&D Canada and Los Alamos National Laboratory on the project (10/21) |
Cangene Corp. |
National Institute of Allergy and Infectious Diseases |
Research and development contract |
To develop a hyper-immune specific for the virus that causes severe acute respiratory syndrome |
The NIAID will supply plasma and funding for the project; terms were not disclosed (10/17) |
Celsion Corp. |
National Institutes of Health |
Licensing agreement |
For the right to develop heat-sensitive gene therapy products activated by microwave heat energy |
Celsion will owe the government a royalty if it develops a product from the technology (9/16) |
Celsion Corp. (AMEX:CLN) |
Duke University |
Exclusive licensing agreement |
For a radiofrequency heating system designed for use with chemotherapeutic drugs for locally advanced breast cancer |
The system is being evaluated in a Phase II trial at Duke (8/7) |
Cepheid Inc. (CPHD) |
FDA |
Purchase agreement |
For 16 Cepheid Smart Cycler processing blocks to be used with basic Smart Cycler II starter systems |
The systems will be used in the food safety testing program (9/8) |
Ceregene Inc.* |
Salk Institute for Biological Studies |
Option agreement |
For exclusive worldwide rights to amyotrophic lateral sclerosis gene therapy technology belonging to the Salk Institute |
Ceregene gained rights to pursue the development and commercialization of the technology (8/8) |
Chemical Diversity Labs Inc.* |
University of New Mexico |
Partnership |
For drug discovery |
The school will use its algorithms to verify the company's computational focusing of targeted libraries and to select a library of small-molecule compounds for screening as potential ligands for a peptide-activated GPCR (7/17) |
CombiMatrix Corp. (CBMX) |
Seattle Biomedical Research Institute |
Collaboration |
To use Combimatrix's chip technology in the area of infectious disease |
Institute researchers will use the technolgogy in various areas in infectious disease; terms were not disclosed (10/9) |
CombiMatrix Corp. (CBMX) |
University of Washington |
Collaboration |
To develop a micro-array-based test for the diagnosis of lymphoma |
CombiMatrix is collaborating with university scientists Daniel Sabath and Stephen Schmechel (9/11) |
Commonwealth Biotechnologies Inc.* |
ND |
Contracts |
To develop and validate detection assays in the general area of biodefense |
Commonwealth said it signed contracts in October worth $1.5M but could not give details (10/14) |
Crucell NV (the Netherlands; CRXL) |
New York University |
Collaboration |
To test Crucell's malaria vaccine in an NYU mouse malaria model |
Crucell expects the first results by the end of the year; terms were not disclosed (10/22) |
Crucell NV (the Netherlands; CRXL) |
Walter Reed Army Institute of Research and GlaxoSmithKline Biologicals |
Cooperative Research and Development Agreement |
To evaluate Crucell's vaccine against malaria |
The vaccine will be tested by itself and in combination with GSK's malaria vaccine candidate, RTS,S; terms were not disclosed (10/22) |
CytoGenix Inc. (OTC BB:CYGX) |
Albert Einstein College of Medicine |
Research agreement |
To study CytoGenix's gene silencing technology against a gene expressed in melanoma cells |
The gene expresses a protein that counteracts the effect of some drugs against hard-to-treat cancers; term were not disclosed (10/30) |
CytRx Corp. (CYTR) |
Massachusetts General Hospital |
Research program |
To use RNAi gene- silencing technology to develop a drug for ALS |
Work is in the area of amyotrophic lateral sclerosis; terms were not disclosed (10/9) |
CytRx Corp. (CYTR) |
University of Massachusetts Medical School |
Research program |
To use RNAi gene- silencing technology to develop a drug for ALS |
CytRx will fund a research program in the area of amyotrophic lateral sclerosis (10/8) |
Entelos Inc.* |
Massachusetts Institute of Technology |
Collaboration |
To better understand the breakdown of communication signals in certain immune system cells |
The collaboration will study the key intracellular communication hubs of lymphocytes to quantitatively map intracellular pathways that respond to different stimuli and then regulate response by the cells (7/17) |
Epigenomics AG* (Germany) |
Wellcome Trust Sanger Institute (UK) |
Collaboration |
To fund and carry out the first phase of the Human Epigenome Protect |
They will identify sites in the human genome at which cytosine bases are modified by DNA methylation, integrate it in the human genome sequence, and then release it to the public (10/7) |
Epimmune Inc. (EPMN) |
National Institute of Allergy and Infectious Diseases |
Contract award |
Contract for design and development of prophylactic HIV vaccines |
Epimmune will lead a consortium that was awarded up to $16.7M over five years to develop epitope-based vaccines (9/29) |
Epimmune Inc. (EPMN) |
National Institute of Allergy and Infectious Diseases |
Contract |
Amended existing contract to include smallpox as target for epitope-based vaccines |
The amendment provides about $0.5M to the contract, bringing it to $2.7M; the five-year contract signed in 1999 includes multiple viral targets (9/25) |
EraGen Biosciences Inc.* |
The Blood Center of Southeastern Wisconsin Inc. |
Collaboration |
To explore methods to reduce lengthy DNA testing |
The collaboration will focus on applications such as blood clotting and bleeding disorders (8/25) |
EsbaTech |
University of Zurich (Switzerland) |
Agreement |
For in silico screening of small-molecule libraries |
The parties will collaborate to improve screening and de novo drug design to identify and optimize inhibitors of the secretase BACE, an Alzheimer's disease target, as well as other undisclosed EsbaTech targets; the company will retain ownership of compounds identified through the screening, triggering a payment upon commercialization to the university (9/17) |
Ganeden Biotech Inc.* |
George Mason University |
Agreement |
To investigate probiotics and immune system therapies that hold promise for U.S. military personnel |
The research involves antimicrobial and antifungal applications for the development of health care products that can be used during training and deployment of troops, both as a prophylaxis and a treatment for noncombat-related illnesses (8/6) |
GeneCo. Inc.* |
San Diego Supercomputing Center |
Licensing agreement |
For GeneCo.'s MetaCore platform |
The center will make MetaCore available to its researchers, as well as researchers at the University of California at San Diego (7/23) |
Gene Logic Inc. (GLGC) |
FDA's Center for Drug Evaluation and Research |
Agreement |
To use Gene Logic's collection of gene expression data from control samples in order to contribute to the evaluation of RNA performance standards for toxicogenomics data |
The goal is to help the FDA assess data quality in the genomics portion of new drug submissions, with the aim of improving drug safety and efficacy and streamlining the discovery and development process (8/19) |
Genome Explorations Inc.* |
Southern Research Institute |
Collaboration |
To pursue joint development programs in target identification using gene expression profiling |
They would co-market individual and combined services (10/27) |
Genta Inc. (GNTA) |
Carnegie Institution of Washington |
Nonexclusive licensing agreement |
To a broad patent covering siRNA |
Genta was drawn to the patents given their fundamental importance in broadly covering processes for introducing RNA into cells to control gene expression (8/15) |
GenVec Inc. (GNVC) |
National Cancer Institute |
Cooperative Research and Development Agreement |
GenVec's lead oncology candidate, TNFerade |
The NCI will conduct a Phase II trial of TNFerade in rectal cancer; they also will test second-generation TNF inhibitors that target tumors (10/23) |
Guava Technologies Inc.* |
University of Birmingham (UK) |
Research alliance |
To explore combining Guava's cell analysis systems with the univer sity's monitoring of cell cultures for apoptosis |
The goal is to accelerate the university's work in that area; terms were not disclosed (9/30) |
Hemispherx Biopharma Inc. (AMEX:HEB) |
Institute for Medical Virology at Johann Wolf- gang Goethe University Hospital (Germany) |
Agreement |
To test two of Hemispherx's compounds against SARS and cancer |
The studies will evaluate the antiviral activity of Ampligen and Alferon (8/11) |
ImmuneRegen BioSciences Inc. (subsidiary of GPN Network Inc.; OTC BB:GPNW) |
Department of Defense |
Expanded collaboration |
For a research study on the effects of Homspera on tested mice after exposure to fatal doses of radiation |
ImmuneRegen will conduct a study with an increased sample size of 16 mice and a reduced number of control mice to four (7/16) |
Immuno-Designed Molecules SA* (France) |
European Union |
Research project |
To develop a celluar vaccine from dendritic cells for prostate cancer |
IDM will work on the project, which gained 12M in funding, with the Children's Cancer Institute in Austria, Etna Biotech, the Instituteo Superiore di Sanita, the Peter McCallum Cancer Institute and the University of Regensburg (10/16) |
Interleukin Genetics Inc. (ILGN) |
University of California at San Francisco |
Collaboration |
To understand the role of inflammation genetics in osteoporosis |
The program is expected to use functional genetic approaches to determine how interleukin-1 genetic variations alter inflammation in the spine leading to vertebral fractures (9/8) |
Large Scale Biology Corp. (LSBC) |
U.S. Army Medical Research Institute of Infectious Diseases |
Research and development agreement |
To apply LSBC's DNA shuffling and molecular evolution technologies to improve agents directed against biowarfare |
The work involves LSBC's Genetic Reassortment by Mismatch Resolution technology; terms were not disclosed (10/21) |
MediGene AG (Germany; FSE:MDG) |
University of Chicago |
Licensing agreement |
MediGene licensed worldwide rights to drug candidates and technology in the area of using oncolytic herpes simplex viruses in treating cancer |
MediGene exercised its option to acquire the exclusive rights; terms were not disclosed (10/15)** |
Meridian Bioscience Inc. (VIVO) |
National Institutes of Health |
Contract |
Meridian got a contract to manufacture clinical-grade recombinant protein Parvovirus B19 vaccine |
The contract was valued at $1.4M and entails production of product for Phase I trials (10/6) |
Nanogen Inc. (NGEN) |
Institute Pasteur (France) |
Licensing agreement |
Patent rights relating to detection of mutations in the GJB2 gene for diagnosis of hereditary deafness |
Nanogen got exclusive rights in Europe; terms were not disclosed (10/28) |
Nanosphere Inc.* |
Northwestern University |
Licensing agreement |
Nanosphere acquired rights to nanoparticle technology for protein biomarkers |
A nanosphere co-founder invented the technology at Northwestern; terms were not disclosed (10/8) |
NaPro BioTherapeutics Inc. (NPRO) |
North Dakota State University |
Research agreement |
For the application of NaPro's non-transgenic gene editing technology in durum wheat |
NaPro will apply its gene editing technology to make single-base pair conversions in the plant genes with the goal of developing improved crop traits (7/23) |
Novavax Inc. (NVAX) |
National Institute of Allergy and Infectious Diseases |
Contract award |
Contract for design and development of a new class of HIV vaccine candidates |
Novavax, as the lead contractor of the award, could receive $16M over five years (9/29) |
Oncolytics Biotech Inc. (Canada; TSE:OSC) |
National Cancer Institute |
Collaborative agreement |
To study Reolysin in a range of cancers |
The NCI approved the drug for collaborative development; the parties will decide on plans for clinical trials (10/29) |
Oncolytics Biotech Inc. (Canada; TSE:OSC) (Spain) |
Institut Catala d-Oncologia are selective for Rasmediated cancers |
Research collaboration |
To develop modified adenoviruses that |
Further details were not disclosed (7/30) |
Orchid BioSciences Inc. (ORCH) |
London's Metropolitan Police Service |
Contract |
To provide scene-of- crime forensic DNA testing services |
The three-year contract is extendable for an additional two years (9/4) |
Orchid BioSciences Inc. (ORCH) |
Houston Police Department |
Contract |
To conduct forensic DNA analysis for new cases as well as retesting for prior cases |
The contract was awarded to Orchid's Cellmark unit (8/4) |
Orchid BioSciences Inc. (ORCH) |
Norway government |
Contract |
To provide DNA testing services to confirm the identity of individuals immigrating to Norway |
The 18-month contract follows Orchid's extendable three-year contract award from the UK government signed last year to provide DNA relationship-testing services to that country's visa department (7/16) |
Orion Genomics LLC* |
Cold Spring Harbor Laboratory |
Agreement |
For Cold Spring to use Orion's GeneThresher sorghum sequences to annotate the genomes of rice and other grasses for the public domain |
The parties plan to release a second annotation of rice genomes early next year (9/16) |
Panacea Pharmaceuticals Inc.* |
Massachusetts General Hospital/ Harvard University |
Agreement |
Granting the company exclusive, worldwide rights to develop and commercialize diagnostic and therapeutic products based on a patented cancer target |
Financial terms were not disclosed (9/15) |
Panacea Pharmaceuticals Inc.* |
Massachusetts Institute of Technology |
Extended and expanded collaboration |
To develop all human, ultra-affinity, single- chain antibodies for Panacea's HAAH oncology program |
The original agreement was signed in December 2000; the company will continue to fund research activities at MIT up to an additional three years and has an option for exclusive worldwide commercialization rights to resulting antibodies (9/10) |
Paradigm Genetics Inc. (PDGM) |
University of North Carolina |
Research collaboration |
To identify biomarkers indicative of choline deficiency |
UNC will provide samples to Paradigm, which will analyze them to identify pathways and mechanisms involved (9/30) |
ParAllele BioScience* |
Baylor College of Medicine |
Research collaboration |
To discover the genetic basis of a specific class of congenital heart abnormalities that affects infants and children and might also increase the risk of heart valve and artery disease in the elderly |
ParAllele will use its single nu- cleotide polymorphism genotyping technology to scan candidate genes to uncover genetic mutations that might lead to the occurrence of left ventricular outflow tract obstruction (7/29) |
Peregrine Pharmaceuticals Inc. (PPHM) |
Keck School of Medicine |
Agreement |
To conduct research on the use of Peregrine's Tumo Necrosis Therapy for immunotherapy for lung cancer |
Keck received a $464,000 grant from the Philip Morris External Research Program to be used for the project (9/9) |
Pieris Proteolab AG* (Germany) |
Technical University of Munich (Germany) |
Alliance |
To conduct further research into lipocalins and anticalins |
Future inventions will either be licensed exclusively to Pieris or in some cases assigned to Pieris; the university will receive research support, milestone payments and royalties (7/24) |
Primagen Holding BV* (the Netherlands) technology developed by the university |
University of British Columbia (Canada) |
Licensing agreement |
To commercialize the mitochondrial DNA detection and toxicity |
Financial terms were not disclosed (9/9) |
Progenics Pharmaceuticals Inc. (PGNX) |
National Institute of Allergy and Infectious Diseases |
Contract award |
Five-year contract for preclinical research development and early clinical testing of a vaccine to prevent HIV |
Progenics could get up to $28.6M over five years under the contract that is subject to the achievement of milestones (9/29) |
ProMetic Life Sciences Inc. (Canada; TSE:PLI) |
National Research Council's Biotechnology Research Institute (Canada) |
Strategic alliance |
For production and bio- purification of therapeutic proteins |
The entities will split any revenues and royalties from the joint venture (9/29) |
Regulome Corp.* |
National Human Genome Research Institute |
Agreement |
Regulome, along with University of Washington researchers, will locate and analyze genetic sequences |
Regulome is being paid $5.3M under the deal related to the ENCODE project; if successful, work will continue to the entire genome (10/9) |
Resverlogix |
University of Calgary |
Agreement |
For Resverlogix to acquire a preclinical cancer therapeutic from the co-discoverers of the technology |
Resverlogix paid C$100,000 (US$71,400) in cash, granted a 10% royalty on future license fees for a five-year period, and issued 2M Series A preferred shares in the transaction (8/19) |
Rubicon Genomics Inc.* |
Wellcome Trust Sanger Institute (UK) |
Agreement |
To amplify DNA for genetic studies of obesity and Type II diabetes |
The institute chose Rubicon's OmniPlex Whole Genome Amplification technology to amplify DNA from 5,000 subjects participating in studies of obesity and Type II diabetes (8/6) |
Sagres Discovery Inc.* |
Genome Institute of Singapore |
Research collaboration |
To determine the global effects of gene mutation in certain cancers and to discover networks of gene expression patterns in such cancers |
The institute will apply its expression profiling technologies and bioinformatics tools to characterize a collection of Sagres' provirus-tagged mouse tumors; Sagres will retain an option to exclusive rights to genes and pathways identified during the collaboration, with commercial terms to be agreed on separately; the institute will retain the right to use such results for its noncommercial research and development (9/16) |
Samaritan Innovative Science Foundation (arm of Samaritan Pharmaceuticals Inc.; OTC BB:SPHC) |
A Harvest Biotech Foundation (Africa) |
Collaboration |
To provide free drugs to children with AIDS in Africa |
Samaritan's HIV drug proved promising, safe and effective through proof-of-concept Phase II trials (9/12) |
Sirna Therapeutics Inc. (RNAI) |
University of Massachusetts Medical School |
Licensing agreement |
For the university's undivided interest in RNA interference IP |
UMMS will receive licensing fees in cash and common stock, and potential milestones; the school also would receive royalties, and the parties will share revenues generated from the sublicensing of the patent (9/9) |
Surromed Inc.* |
National Heart Blood and Lung Institute |
Contract award |
To apply biological marker technology to samples of patients with in-stent restenosis |
Surromed was awarded a contract to perform proteomic and metabolic profiling; the NIH will do gene expression analysis of the same samples (10/29) |
Surromed Inc.* |
Comprehensive Care Center at Wake Forest University |
Collaboration |
To collect and analyze clinical samples in prostate and renal cell cancer |
Surromed said the deal marks a step in its program to develop cancer diagnostics; terms were not disclosed (10/15) |
TaiGen Biotechnology Co. Ltd. (Taiwan) |
Executive Yuan (China) |
Research agreement |
To discover and develop drugs that target the coronavirus that causes SARS |
TaiGen is receiving US$890,000 to cover half the first-year cost of the program that could last six years; TaiGen is working with various research groups in the effort (10/22) |
Theratopis (France) |
Robarts Research Institute (Canada) |
Research collaboration |
To identify cytoprotective molecules that inhibit apoptosis |
Theratopis has worldwide rights to any resulting products; terms were not disclosed (10/15)** |
Tm Bioscience Corp. (Canada; TSE: TMC) |
Mayo Foundation |
Purchase agreement |
For Tm's Tag-It P450-2D6 drug metabolism test |
Tm said the test would be used by Mayo Medical Laboratories, which provides lab testing and interpretive services for Mayo and other worldwide medical centers and hospitals (9/17) |
TransForm Pharmaceuticals Inc.* |
U.S. Defense Advanced Research Projects Agency |
Contract |
To develop a prototype system for the discovery of methods and compositions to control in vitro cell differentiation |
The system will enable micro- array based screening of com- plex mixtures that control and promote cell growth and differentiation (7/17) |
VaxGen Inc. (VXGN) |
U.S. Army Medical Research Institute of Infectious Diseases |
Licensing agreement |
Vaxgen received exclusive worldwide rights to a recombinant anthrax vaccine based on USAMRIID technology |
Vaxgen will pay various fees for rights as well as milestones and royalties; it has been using the technology under a deal entered in 2002 (10/13) |
VaxGen Inc. (VXGN) |
National Institute of Allergy and Infectious Diseases |
Contract |
To support development of VaxGen's anthrax can- didate, rPA102 |
The three-year grant is intended to fund animal and Phase II studies, scale-up and validation, and production of 3 million doses (9/30) |
VaxGen Inc. (VXGN) |
Health Protection Agency for England and Wales (UK) |
Agreement |
To negotiate terms under which VaxGen would license UK rights to, and transfer technology for, its recombinant anthrax vaccine candidate to HPA |
The agreement would give HPA the right to manufacture the vaccine in the UK and possibly other territories (9/4) |
Vical Inc. (VICL) |
National Institute of Allergy and Infectious Diseases |
Cooperative Research and Development Agreement |
For development and preclinical evaluation of DNA vaccines against West Nile virus |
The CRADA, from the NAIAD's Vaccine Research Center, includes an option for Vical to secure rights to resulting technology (10/20) |
Vical Inc. (VICL) |
Vaccine Research Center of the NIAID |
Manufacturing contract |
DNA vaccine against SARS |
Vical was granted a contract to manufacture clinical-grade supplies (10/13) |
Wilex AG* (Germany) |
Fox Chase Cancer Center |
Agreement |
To develop Wilex's WX- UK1 for the antimeta-static treatment of advanced breast cancer patients at Fox Chase |
The U.S. Department of Defense awarded a $3.9M grant for the project (9/4) |
XTL Biopharmaceuticals Inc..* (Israel) |
Stanford University |
Licensing agreement |
For rights to a series of neutralizing human monoclonal antibodies to hepatitis C |
XTL licensed exclusive rights except in China in return for milestone and royalty obligations (10/13) |
| | ||||
Notes: | ||||
This chart does not include grant agreements (unless they also are part of a larger collaboration) or agreements between biotech companies and clinical trial centers. | ||||
* Denotes privately held company. | ||||
** Denotes date item ran in BioWorld International. | ||||
@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted. | ||||
Unless otherwise noted, shares are traded on the Nasdaq exchange. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE= Copenhagen Stock Exchange; FSE == Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||
